SCHEMBL18329477

SCHEMBL18329477

COC(=O)c1c(Cl)ccc(C)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
TSHR P16473 3/20 0.41
GAA P10253 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TAS1R3 Q7RTX0 3/20 0.40
TAS1R1 Q7RTX1 3/20 0.40
CYP3A4 P08684 2/20 0.40
ACHE P22303 1/20 0.40
GUSB P08236 1/20 0.39
TAS1R2 Q8TE23 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23362891 0.87 PTGS2 (0.43) PTGS2CA12CA1CA2CA7
SCHEMBL18329542 0.85 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL1671329 0.83 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL8488636 0.82 ABL1 (0.45) PTGS2CA12CA1CA2CA7
SCHEMBL1495245 0.82 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL3205636 0.81 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL31284126 0.81 TSHR (0.40) CA12CA1CA2CA7CA9
SCHEMBL29570135 0.81 TSHR (0.40) CA12CA1CA2CA7CA9
SCHEMBL1164172 0.79 ALDH1A1 (0.48) GAALMNAALDH1A1KDM4EHSD17B10
SCHEMBL3829091 0.79 DPP4 (0.50) PTGS2GAAALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230100534-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT UBE CORPORATION (JP) 2023-03-30 US disclosed
US-20230100534-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT UBE CORPORATION (JP) 2023-03-30 US disclosed
US-11407831-B2 Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent UBE INDUSTRIES, LTD. (JP) 2022-08-09 US disclosed
CN-107735401-B Substituted dihydropyrrolopyrazole derivatives 宇部兴产株式会社 2021-08-31 CN disclosed
US-10894798-B2 Substituted dihydropyrrolopyrazole derivative UBE INDUSTRIES, LTD. (JP) 2021-01-19 US disclosed
US-10894798-B2 Substituted dihydropyrrolopyrazole derivative UBE INDUSTRIES, LTD. (JP) 2021-01-19 US disclosed
EP-3705124-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT Ube Industries, Ltd. (JP) 2020-09-09 EP disclosed
EP-3705124-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT Ube Industries, Ltd. (JP) 2020-09-09 EP disclosed
US-20200262924-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT UBE INDUSTRIES, LTD. (JP) 2020-08-20 US disclosed
US-20200262924-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT UBE INDUSTRIES, LTD. (JP) 2020-08-20 US disclosed
US-20190256531-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2019-08-22 US disclosed
US-20190256531-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2019-08-22 US disclosed
US-10273252-B2 Substituted dihydropyrrolopyrazole derivative UBE INDUSTRIES, LTD. (JP) 2019-04-30 US disclosed
US-10273252-B2 Substituted dihydropyrrolopyrazole derivative UBE INDUSTRIES, LTD. (JP) 2019-04-30 US disclosed
US-20180186818-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2018-07-05 US disclosed
US-20180186818-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2018-07-05 US disclosed
US-20180186818-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2018-07-05 US disclosed
EP-3309163-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE Industries, Ltd. (JP) 2018-04-18 EP disclosed
EP-3309163-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE UBE Industries, Ltd. (JP) 2018-04-18 EP disclosed
WO-2016204153-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE 宇部興産株式会社 2016-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256531-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE QDPR, CYP11B2, CYP4F3 PTGS2 2472/4885CA12 3634/4885CA1 3470/4885
US-20230100534-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT IL2, CYP2D6, IL2RA PTGS2 2847/4885CA12 1428/4885CA1 2937/4885
US-10894798-B2 Substituted dihydropyrrolopyrazole derivative QDPR, CYP11B2, CYP4F3 PTGS2 2472/4885CA12 3634/4885CA1 3470/4885
US-20200262924-A1 PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT IL2, CYP2D6, CYP3A43 PTGS2 3158/4885CA12 1789/4885CA1 3394/4885
US-11407831-B2 Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent IL2, CYP2D6, CYP3A43 PTGS2 3158/4885CA12 1789/4885CA1 3394/4885
US-10273252-B2 Substituted dihydropyrrolopyrazole derivative QDPR, CYP11B2, CYP4F3 PTGS2 2472/4885CA12 3634/4885CA1 3470/4885
US-20180186818-A1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE QDPR, CYP11B2, CYP4F3 PTGS2 2472/4885CA12 3634/4885CA1 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.